–
Neumora Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−237
FY22:
−136
FY23:
−252
FY24:
−263
FY25:
−241
(positive)
Change from FY21 to FY25
millions USD
FY21:
−237
FY22:
−135
FY23:
−251
FY24:
−263
FY25:
−233
(positive)
Change from FY21 to FY25
millions USD
FY21:
−237
FY22:
−131
FY23:
−236
FY24:
−244
FY25:
−237
(positive)
Change from FY21 to FY25
millions USD
FY21:
−237
FY22:
−131
FY23:
−236
FY24:
−244
FY25:
−237
All amounts in millions USD FY21: figures supplemented from Twelve Data because the SEC filings do not reach back this far.